Skip to main content

Advertisement

Table 3 The 5-, 10-, and 20-year survival rates for the 46 NPC patients at different stages

From: Forty-six cases of nasopharyngeal carcinoma treated with 50 Gy radiotherapy plus hematoporphyrin derivative: 20 years of follow-up and outcomes from the Sun Yat-sen University Cancer Center

Item OS rate (%) P value LRFS rate (%) P value DMFS rate (%) P value DFS rate (%) P value
5-year 10-year 20-year 5-year 10-year 20-year 5-year 10-year 20-year 5-year 10-year 20-year
Clinical stagea
 I 66.7 66.7 66.7 0.979 66.7 66.7 66.7 0.019 100 100 100 0.072 66.7 66.7 66.7 <0.001
 II 70.0 30.0 30.0 92.3 82.1 82.1 82.1 82.1 82.1 75.2 64.5 64.5
 III 73.8 39.1 29.0 73.6 60.2 42.2 90.4 84.0 84.0 70.4 53.2 37.2
 IV 85.7 42.9 14.3 25.7 25.7 25.7 31.2 31.2 31.2 0 0 0
T stagea
 T1 80.0 26.7 26.7 0.996 87.5 58.3 58.3 0.020 85.7 68.6 68.6 0.066 58.3 43.8 43.8 <0.001
 T2 66.7 44.4 33.3 88.9 88.9 88.9 88.9 88.9 88.9 77.8 77.8 77.8
 T3 72.7 36.4 30.3 72.1 64.9 45.4 89.9 89.9 89.9 68.6 49.7 39.7
 T4 85.7 42.9 14.3 25.7 25.7 25.7 31.2 31.2 31.2 0 0 0
N stagea
 N0 58.3 29.2 29.2 0.992 80.8 80.8 80.8 <0.001 90.9 90.9 90.9 0.068 71.6 71.6 71.6 0.005
 N1 67.9 39.3 31.2 75.6 69.8 55.9 78.3 78.3 78.3 55.4 50.3 40.3
 N2 83.3 50.0 16.7 60.0 20.0 0 80.0 60.0 60.0 60.0 20.0 0
 N3 0 0 0 0 0 0 0 0 0 0 0 0
  1. NPC nasopharyngeal carcinoma; OS overall survival; LRFS local recurrence-free survival; DMFS distant metastasis-free survival; DFS disease-free survival
  2. a As defined by the criteria of the seventh edition of the AJCC staging system for NPC